Stocktoria
Viridian Therapeutics, Inc.DE VRDN
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2014-06-18
Viridian Therapeutics, Inc.DE financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $70.8M | $302,000 | $314,000 | $1.8M | $3.0M | $1.1M | $4.5M | $8.4M | $4.0M | $3.5M |
| R&D expense | — | — | — | — | — | — | $34.8M | $30.4M | $19.6M | $13.7M |
| SG&A expense | $95.3M | $61.1M | $95.0M | — | — | — | — | — | — | — |
| Operating income | -$363.4M | -$299.0M | -$254.4M | -$134.3M | -$79.7M | -$110.4M | -$42.0M | -$33.1M | -$26.5M | -$17.0M |
| Interest expense | — | — | — | $500,000 | — | — | — | — | — | $95,000 |
| Income tax | $0 | — | — | — | — | — | — | — | — | — |
| Net income | -$342.6M | -$269.9M | -$237.7M | -$129.9M | -$79.4M | -$110.7M | -$41.9M | -$32.7M | -$26.5M | -$17.3M |
| EPS (diluted) | — | — | $-5.31 | $-4.05 | $-6.66 | $-31.13 | — | — | — | — |
| Operating cash flow | -$276.4M | -$232.3M | -$184.2M | -$93.8M | -$54.6M | -$29.8M | -$36.1M | -$26.8M | -$28.2M | -$14.8M |
| Free cash flow | -$276.9M | -$232.8M | -$185.1M | -$94.6M | -$54.9M | -$29.8M | -$36.1M | -$27.3M | -$28.4M | -$15.0M |
| Cash & equivalents | — | — | — | — | — | — | — | $32.6M | $47.4M | $22.1M |
| Inventory | — | — | — | — | — | — | — | — | — | $64,000 |
| Total assets | $899.4M | $742.4M | $490.4M | $435.1M | $203.7M | $131.3M | $30.3M | $66.1M | $52.5M | $24.8M |
| Total liabilities | $177.3M | $70.8M | $48.4M | $40.0M | $16.0M | $11.2M | $14.5M | $14.8M | $14.0M | $9.7M |
| Shareholders' equity | $722.2M | $671.6M | $442.0M | $395.1M | $187.7M | $120.0M | $15.8M | $51.3M | $38.5M | -$61.9M |
Growth · year-over-year · Revenue CAGR 39.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +23359.9% | -3.8% | -82.3% | -40.2% | +182.2% | -76.5% | -46.8% | +109.5% | +15.1% | -39.1% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.